RELEX-SOLUTIONS
3.1.2024 09:31:35 CET | Business Wire | Press release
Today, RELEX Solutions, provider of unified supply chain and retail planning solutions, announced it has acquired Optimity, a supply chain planning and optimization provider. The acquisition will bolster the RELEX retail and supply chain platform with daily production planning, optimization and production scheduling capabilities which are crucial for the end-to-end consumer goods value chain.
“The consumer goods industry is incredibly dynamic and complex. Acquiring Optimity will seamlessly link downstream demand with upstream planning, so consumer goods companies can more accurately predict consumer demand, optimize production plans and schedules, adjust inventory levels, and respond quickly to market changes or unexpected disruptions,” said Mikko Kärkkäinen, co-founder and group CEO, RELEX. “This acquisition also further accelerates our vision towards an adaptive, autonomous and synchronized supply chain unifying demand and supply planning decisions in one platform to minimize all wasted cost and product. We warmly welcome the Optimity team to RELEX.”
Optimity, with global headquarters in Sweden and offices around the world, offers a broad supply chain planning and optimization solution specifically for manufacturers and distributors. Optimity enables customers to make optimal supply chain decisions from strategic levels to detailed production scheduling. Their offerings include demand planning, production planning and scheduling, supply planning, distribution planning, inventory optimization, and S&OP. With 80+ customers across the food and beverage, and complex manufacturing industries, Optimity’s experience augments RELEX’s expertise across retail and consumer goods markets.
The acquisition brings together a highly complementary offering between the two organizations, enabling RELEX to extend and deepen its production planning and supply chain optimization capabilities, such as synchronized daily production planning, optimization and scheduling in the food & beverage and manufacturing sector.
New or expanded capabilities within the RELEX unified retail and supply chain planning platform from Optimity include:
- Production planning: Create optimized production plans from up-to-date forecasts to balance operational costs and flexibility while considering production restrictions, material constraints and business priorities.
- Production scheduling: Generate and manage optimized production schedules built around constraints to reduce changeover time and bolster manufacturing efficiency.
- Network balancing: Rectify imbalances in complex distribution networks to minimize risks, reduce costs, and boost operational efficiency.
- Distribution planning: Gain complete distribution network visibility to make smarter, proactive decisions aligned with business objectives and customer service goals.
- Purchase planning: Balance supply-side complexity with end-to-end visibility to pinpoint the most efficient and profitable way to fulfill demand plans and customer obligations.
“Our depth in some of the most complex consumer goods industries like bakery, ready-made meals, protein production and industrial manufacturing complements the vast understanding of consumer demand that RELEX has, based on their impressive expertise managing more than $700 billion of demand in grocery alone,” said Christer Liden, CEO, Optimity. “We are thrilled to join the RELEX team and further optimize the consumer goods value chain together.”
To learn more about the acquisition, please visit this page.
About RELEX
RELEX Solutions helps retailers and consumer brands drive profitable growth across all sales and distribution channels by maximizing customer satisfaction and minimizing operative costs. Our market-leading, unified supply chain and retail planning platform helps retailers and consumer goods companies align and optimize demand, merchandising, supply chain, and operations planning across the end-to-end value chain. We drive record-high product availability, increased sales, improved sustainability, and the best return on investment in inventory, space, workforce, and capacity. Leading brands like Dollar Tree and Family Dollar, Stokke, Rite Aid, Sprouts Farmers Market, AutoZone, and PetSmart trust RELEX to optimize their supply chain and retail planning. Go to relexsolutions.com for more.
About Optimity
For nearly two decades, Optimity has challenged the supply chain planning space. Optimity has provided companies with user-friendly yet powerful planning software to optimize even the most intricate supply chains. We believe every supply chain can maximize profits effortlessly with the right tools. Optimity delivers a comprehensive solution, covering strategic optimization to detailed production scheduling. Our expert team, boasting years of industry knowledge, ensures success in every project. Supply chain planning is pivotal for manufacturing and distribution, and Optimity excels in delivering solid solutions for complex supply chains. Our integrated planning tool ensures profitability, simplifying processes for sustainable growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240103171132/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom